What does this article add to?
  1. This manuscript attempts to establish the efficacy and safety of mirabegron-tamsulosin combination therapy versus the routinely used tamsulosin alpha blocker monotherapy in a subset of Indian population with ‘symptomatic BPH with predominantly coexisting OABS’ as a De-novo therapeutic measure. This article is novel for its unique de-novo utility of using mirabegron-tamsulosin combination therapy initially from the start in medicine naive virgin select patients of ‘LUTS due to BPH with OABS’ as opposed to the majority of published research utilising mirabegron mainly in an add on therapy fashion to manage residual BPH-OAB symptoms post alpha blocker therapy.
  2. This manuscript also especially focuses closely on investigating whether there was of any occurrence of rising PVR and urinary retention, associatied specifically with the concomitant use of initial mirabegron –tamsulosin combination therapy for ‘LUTS due to BPH with OABS’ without the add on therapy protocol as the current literature regarding mirabegron and its effect on PVR is ambiguous about the same.
  3. The current results of this research adds to the clarity in the literature and strengthens the notion of utilizing mirabegron combination therapy as a start-up therapy without the apparent fear of inducing any rise in the incidence of PVR and urinary retention as opposed to the usually employed add on protocol in majority of patients of ‘LUTS due to BPH with OABS’. This measure in itself is novel attempt to change the global perception of practicing urologists towards mirabegron’s utility in the medical management of symptomatic patients of BPH with OABS.